Pharmacogenomics: questions and concerns.
The progressively aging population in the western world, rising socioeconomic expenditure and increasing costs for the treatment of adverse drug reactions, lead to increasing pressure on public spending. The public acceptance of pharmacogenomics is high, therefore, because it promises individualized safe and effective treatment at lower cost. Pharmacogenomics studies the genetic polymorphisms that underlie the variability in drug response between individuals. Despite the great benefits being awaited from this new field, a number of ethical, social and legal concerns arise, which demand rapid strict international regulations in order to prevent discrimination or harm of any kind from society, industry, groups or individuals.
Mahlknecht
Ulrich
U
University of Heidelberg Medical Center, Department of Hematology/Oncology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Ulrich.Mahlknecht@med.uni-heidelberg.de
Voelter-Mahlknecht
Susanne
S
D003695:Delivery of Health Care; D004345:Drug Industry; D004358:Drug Therapy / Q000941:ethics* / Q000592:standards; D005820:Genetic Testing; D014644:Genetic Variation; D005828:Genetics, Population; D006801:Humans; D010597:Pharmacogenetics / Q000191:economics* / Q000941:ethics* / Q000592:standards